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Abstract: PURPOSE Increased angiogenesis after myocardial infarction is considered an important fa-
vorable prognostic parameter. The ฀v฀3 integrin is a key mediator of cell-cell and cell-matrix interactions
and an important molecular target for imaging of neovasculature and repair processes after MI. Thus,
imaging of ฀v฀3 expression might provide a novel biomarker for assessment of myocardial angiogenesis
as a prognostic marker of left ventricular remodeling after MI. Currently, there is limited data available
regarding the association of myocardial blood flow and ฀v฀3 integrin expression after myocardial infarc-
tion in humans. METHODS Twelve patients were examined 31 ± 14 days after MI with PET/CT using
[18F]Galacto-RGD and [13N]NH3 and with cardiac MRI including late enhancement on the same day.
Normal myocardium (remote) and areas of infarction (lesion) were identified on the [18F]Galacto-RGD
PET/CT images by correlation with [13N]NH3 PET and cardiac MRI. Lesion/liver-, lesion/blood-, and
lesion/remote ratios were calculated. Blood flow and [18F]Galacto-RGD uptake were quantified and
correlated for each myocardial segment (AHA 17-segment model). RESULTS In 5 patients, increased
[18F]Galacto-RGD uptake was notable within or adjacent to the infarction areas with a lesion/remote
ratio of 46% (26-83%; lesion/blood 1.15 ± 0.06; lesion/liver 0.61 ± 0.18). [18F]Galacto-RGD uptake
correlated significantly with infarct size (R = 0.73; p = 0.016). Moreover, it correlated significantly with
restricted blood flow for all myocardial segments (R = - 0.39; p < 0.0001) and even stronger in severely
hypoperfused areas (R = - 0.75; p < 0.0001). CONCLUSION [18F]Galacto-RGD PET/CT allows the
visualization and quantification of myocardial ฀v฀3 expression as a key player in angiogenesis in a subset of
patients after MI. ฀v฀3 expression was more pronounced in patients with larger infarcts and was generally
more intense but not restricted to areas with more impaired blood flow, proving that tracer uptake was
largely independent of unspecific perfusion effects. Based on these promising results, larger prospective
studies are warranted to evaluate the potential of ฀v฀3 imaging for assessment of myocardial angiogenesis
and prediction of ventricular remodeling.
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Abstract
Purpose Increased angiogenesis after myocardial infarction is considered an important favorable prognostic parameter. The αvβ3
integrin is a key mediator of cell-cell and cell-matrix interactions and an important molecular target for imaging of neovasculature
and repair processes after MI. Thus, imaging of αvβ3 expression might provide a novel biomarker for assessment of myocardial
angiogenesis as a prognostic marker of left ventricular remodeling after MI. Currently, there is limited data available regarding the
association of myocardial blood flow and αvβ3 integrin expression after myocardial infarction in humans.
Methods Twelve patients were examined 31 ± 14 days after MI with PET/CT using [18F]Galacto-RGD and [13N]NH3 and with
cardiac MRI including late enhancement on the same day. Normal myocardium (remote) and areas of infarction (lesion) were
identified on the [18F]Galacto-RGD PET/CT images by correlation with [13N]NH3 PET and cardiac MRI. Lesion/liver-, lesion/
blood-, and lesion/remote ratios were calculated. Blood flow and [18F]Galacto-RGD uptake were quantified and correlated for
each myocardial segment (AHA 17-segment model).
Results In 5 patients, increased [18F]Galacto-RGD uptake was notable within or adjacent to the infarction areas with a lesion/
remote ratio of 46% (26–83%; lesion/blood 1.15 ± 0.06; lesion/liver 0.61 ± 0.18). [18F]Galacto-RGD uptake correlated signifi-
cantly with infarct size (R = 0.73; p = 0.016). Moreover, it correlated significantly with restricted blood flow for all myocardial
segments (R = − 0.39; p < 0.0001) and even stronger in severely hypoperfused areas (R = − 0.75; p < 0.0001).
Conclusion [18F]Galacto-RGD PET/CT allows the visualization and quantification of myocardial αvβ3 expression as a key
player in angiogenesis in a subset of patients after MI. αvβ3 expression was more pronounced in patients with larger infarcts and
was generally more intense but not restricted to areas with more impaired blood flow, proving that tracer uptake was largely
independent of unspecific perfusion effects. Based on these promising results, larger prospective studies are warranted to evaluate
the potential of αvβ3 imaging for assessment of myocardial angiogenesis and prediction of ventricular remodeling.
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Introduction
Myocardial infarction (MI) and subsequent left ventricular
(LV) remodeling is the most frequent underlying cause for
the development of chronic heart failure [1, 2]. LV re-
modeling is characterized by complex cellular and struc-
tural processes leading to progressive LV dilatation and
deterioration of cardiac function [3]. The extent of myo-
cardial damage is an important determinant of both prog-
nosis and the risk of remodeling after MI [4, 5]. After
initial cell death, myocardial tissue in infarcted areas un-
dergoes a healing process associated with inflammation,
angiogenesis, fibroblast proliferation, and collagen ex-
pression resulting in scar formation [1]. Poor infarct
healing and infarct expansion during this phase can influ-
ence LV geometry and contribute to progressive remodel-
ing [1, 6]. Modifications of the angiogenic response to
ischemia have been investigated as potential treatment
strategies to limit infarct size and prevent LV remodeling
[7, 8]. The efficacy of these therapies is usually assessed
by measurement of perfusion or functional parameters [9,
10]. However, results have been variable and sometimes
inconclusive, indicating the need for specific imaging
tools for monitoring of angiogenesis and ventricular re-
modeling. Therefore, novel biomarkers for the assessment
of LV remodeling are needed. One of the key players in
these processes is the integrin αvβ3. It is a heterodimeric
glycoprotein receptor that is highly expressed on endothe-
lial cells during angiogenesis and also on other cells like
myofibroblasts [11, 12]. Its expression is upregulated after
ischemic myocardial injury in infarcted and border zone
regions as part of the early infarct healing process
[13–15]. Increased angiogenesis after myocardial infarc-
tion is generally considered a favorable prognostic param-
eter [8, 13, 16–18]. The integrin αvβ3 could therefore
represent a novel biomarker after MI to predict adverse
LV remodeling processes. Radiolabeled antagonists con-
taining a cyclic Arg-Gly-Asp (RGD) peptide have been
used for molecular imaging of αvβ3 integrin expression
in oncology and after experimental and human MI using
radionuclide imaging [13–15, 17–26]. The first PET tracer
used clinically for αvβ3 imaging was [18F]Galacto-RGD
[27, 28]. This radiotracer is based on the highly αvβ3
specific cyclic pentapeptide cRGDfK, developed by the
group of Kessler et al. [29, 30]. There is evidence sug-
gesting that indeed imaging of αvβ3 integrin expression
with [18F]Galacto-RGD after MI is feasible and associated
with post-MI LV remodeling [16]. Imaging of αvβ3 after
MI therefore seems promising and αvβ3 could represent a
novel imaging biomarker for the assessment of LV re-
modeling in clinical practice. It has been shown that im-
aging of αvβ3 expression in patients after MI is feasible
using SPECT [12, 13, 31, 32]. Compared with PET,
SPECT imaging has several limitations in the clinical set-
ting. Its sensitivity and spatial resolution are lower and
quantification of tracer uptake can be challenging.
Furthermore, data on αvβ3 imaging after myocardial in-
farction using PET is limited, and in particular little is
known about the relationship of myocardial blood flow
and αvβ3 expression in this scenario.
Thus, the purpose of this study was to evaluate the feasi-
bility of [18F]Galacto-RGD PET in patients after acute MI for
αvβ3 expression assessment. In particular, we examined the
correlation of αvβ3 expression with myocardial blood flow
and infarct extent as quantified by PET.
Materials and methods
Patients
Patient characteristics are summarized in Table 1. Twelve pa-
tients, all male, with acute MI were examined with
[18F]Galacto-RGD PET/CT (mean age 53 ± 12 years, range
35–78 years). Inclusion criteria were history of acute myocar-
dial infarction with successful revascularization within
7 weeks before scanning. Seven (58%) patients suffered a
ST-elevation myocardial infarction (STEMI), while 5 patients
(42%) suffered a Non-ST-elevation myocardial infarction
(NSTEMI). Further inclusion criteria were age over 18 years,
and the ability to give written and informed consent.
Exclusion criteria were pregnancy, lactation period, and im-
paired renal function (serum creatinine level > 1.2 mg/dl). The
vast majority of patients were not on typical cardiological
medication such as ASA, statins, beta blockers, diuretics, or
ACE inhibitors/AT II antagonists at the time of the infarction.
Only one patient received a drug of the group ACE inhibitors/
AT II antagonists due to hypertension. Further patient charac-
teristics including cardiovascular risk factors, number of dis-
eased vessel, and medication taken prior to and after myocar-
dial infarction are summarized in Table 1.
All patients underwent PET/CT with [18F]Galacto-RGD
and [13N]NH3 within the same imaging session. On the same
day cardiac magnetic resonance imaging (MRI) was per-
formed, including CINE sequences for assessment of LV
function and volume, as well as late enhancement images after
administration of i.v. contrast to evaluate scar formation.
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Informed written consent was obtained from all patients.
The ethics committee of our university approved the study
protocol.
Radiopharmaceuticals
Synthesis of the precursor and subsequent [18F]-labeling of
Galacto-RGD and synthesis of [13N]NH3 were carried out as
described previously [33].
[18F]Galacto-RGD PET/CT imaging
Imaging was performed with a Biograph Sensation 16 PET/
CT scanner (Siemens, Forchheim, Germany). One hundred
twenty minutes after injection of [18F]Galacto-RGD (188 ±
19 MBq), an emission scan was performed in the 3D mode
covering the area of the heart (three-dimensional mode; 1 bed
position, 15 min acquisition time). This time of imaging was
chosen to achieve an optimal signal-to-noise ratio based on
previous work [28, 34]. Subsequently, an unenhanced low-
dose CT scan (120 kV, 25 mAs, collimation 16 × 0.75 mm)
was carried out in shallow expiration. For attenuation correc-
tion, the CT data were converted from Hounsfield units (HU)
to linear attenuation coefficients for 511 keV using a single
CT energy scaling method based on a bilinear transformation.
Emission data were corrected for randoms, dead time, and
attenuation and reconstructed using the ordered-subsets ex-
pectation maximization (OSEM) algorithm using 8 iterations
and 4 subsets. For noise reduction, a Gaussian filter with a
FWHM of 5 mm was applied.
[13N]NH3 PET/CT
For perfusion quantification, [13N]NH3 (740 MBq) was ad-
ministered. Each acquisition consisted of 21 frames (12 × 10 s,
6 × 30 s, 3 × 300 s). Using an analysis program developed at
our institution (MunichHeart/NM), the absolute flow was cal-
culated based on a validated three-compartment tracer kinetic
model [35].
Magnetic resonance imaging
MRI was performed on a 1.5 T imaging system (Achieva;
Philips Healthcare, Best, Netherlands) with a dedicated five-
channel cardiac coil. After acquisition of scout views, a long-
axis view, two- and four-chamber views and short-axis views
of the left ventricle were obtained. Gadopentetate
dimeglumine (Magnevist; Bayer Schering Pharma AG,
Berlin, Germany) was administered at 0.2 mmol per kilogram
of body weight via an antecubital venous access. The admin-
istration of gadopentetate dimeglumine was followed by a 20-
ml saline injection. Delayed enhancement imaging was started
15–20 min after injection of gadopentetate dimeglumine.
Optimization of inversion time (TI) was performed using a
standard Look–Locker (turbo field echo–echo planar imaging
(EPI)) sequence. This pulse sequence is used to determine the
correct TI to null the signal intensity (SI) of normal myocar-
dium. Sequence parameters of the Look–Locker sequence in-
clude field of view (FOV), 270 × 270 mm; matrix, 128 × 99;
slice thickness, 10 mm; in-plane resolution, 2.1 × 2.2 mm;
repetition time (TR)/echo time (TE), 40/5.7 ms; flip angle,
15°; and EPI factor 9. The k-space was read out with a centri-
cally reordered technique. All delayed enhancement imaging
was performed using prospective ECG-triggering in the
breath-hold technique. Data acquisition was performed during
the mid-diastole, which was estimated by a time window of
minimal cardiac motion. 15–20 min after injection of
gadopentetate dimeglumine, a segmented 2D IR–GE
(inversion-recovery gradient echo) sequence was started. For
both IR sequences, a T1 GE technique was applied. The se-
quence has the following parameters: TR/TE, 3.6/1.2 ms;
bandwidth, 382 Hz per pixel; flip angle: 25°, a typical FOV
of 320 × 320 mm (individually adapted); matrix, 160 × 160;
Table 1 Patient characteristics and details on infarct characteristics
Included patients






Diabetes mellitus 3 (25%)





No. of diseased vessels
1-vessel disease 8 (67%)
2-vessel disease 2 (17%)




Previous myocardial infarction 0 (0%)
S/p CABG 0 (0%)
Medication Prior to infraction After infraction
ASS 0 (0%) 12 (100%)
Statin 0 (0%) 12 (100%)
Beta blocker 0 (0%) 12 (100%)
Diuretics 0 (0%) 6 (50%)
ACE inhibitors/AT II antagonists 1 (8%) 12 (100%)
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and number of signal averages 52. The acquired voxel size
was 2.0 × 2.0 × 8 mm, reconstructed as 1.25 × 1.25 × 8 mm.
Image analysis
The corrected emission scans were calibrated to standardized
uptake values (SUVs; measured activity concentration [Bq/
ml] × body weight [g]/injected activity [Bq]). Images were
analyzed on a multimodality workplace (MMWP) worksta-
tion (Siemens, Erlangen, Germany) (see also Fig. 1 for an
example of definition of infarct area and area of
[18F]Galacto-RGD uptake).
For measurement of tracer uptake in [13N]NH3 PET, the
area of infarction was defined by comparison of [13N]NH3
PET with the normal database.
The ROI for the quantification of the [18F]Galacto-RGD
uptake was manually drawn into the polar map of the
[18F]Galacto-RGD PET data. The goal was to reflect the
post-ischemic infarct area in this polar map. To achieve
this, not only the [18F]Galacto-RGD PET itself but also
the [13N]NH3 PET images and the MRI images were used
as reference. In the case of a low [18F]Galacto-RGD uptake
or an uptake below the remote myocardium, the ROI was
based mainly on the [13N]NH3 PET and MRI images. To
quantify the [18F]-Galacto-RGD uptake in the remote myo-
cardium, a ROI map was drawn in the opposite myocardial
areas without [18F]-Galacto-RGD uptake, which were
clearly not affected by the infarction, i.e., in areas without
blood flow impairment in [13N]NH3 PET or late gadolini-
um enhancement in cardiac MRI.
Uptake ratios were calculated as follows: (Uptake [Lesion]/
Uptake [Remote OR Blood OR Liver], where “Lesion”,
“Remote,” “Blood,” and “Liver” refer to the tracer uptake in
the infarct area, the healthy remote myocardium, the blood, or
the liver, respectively. Lesion/remote ratio was expressed as
percentage in order to better illustrate the difference between
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Fig. 1 Image analysis in a patient with inferior wall myocardial
infarction. Cardiac MRI (A: short axis late enhancement images) shows
intense contrast enhancement in the inferior wall with central no reflow
phenomenon indicative of a severe transmural infarction (red arrows).
[13N]NH3 PET (B, F: polar maps; D, H: comparison with normal
database) shows severely impaired blood flow in the inferior wall, the
areas coded in red in D indicate areas with substantially lower flow
compared with normal myocardium in a reference population, and the
areas in blue in H indicate areas defined as infarcted using a threshold of
0.5 ml/min/g. [18F]Galacto-RGD PET/CT (C: polar map without ROIs,
G: polar map after manual delineation of the ROI for the infarct area
(white) and the remote myocardium without increased [18F]Galacto-
RGD uptake, with normal perfusion and without late gadolinium en-
hancement (red); E: short axis PET/CT fusion image) shows pronounced
tracer uptake in the area of infarction in the inferior wall with no tracer
uptake in normal remote myocardium
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of 20% indicates that the uptake in the infarct area is 20%
above the remote myocardium).
Additionally, for all myocardial segments according to the
American Heart Association (AHA) 17-segment model,
SUVs for [18F]Galacto-RGD PET and flow in [13N]NH3were
calculated and correlated. Definition of infarcted segments
was flow of less than 0.5 ml/min/g.
All data sets for the assessment of late enhancement MR
imaging of the left and right ventricle were viewed on Totoku
monitors (ME 203L, Totoku, Japan). The transmural extent
and patterns were evaluated based on the segmentation model
of the American Heart Association Guidelines. LE was de-
fined as present only when detectable in two orthogonal
planes.
Statistical analysis
Signal intensities determined for the different regions are
expressed as mean ± standard error of the mean (SEM) or in
box-and-whisker plots with median, 25th–75th percentile and
lowest to highest value. Differences between the different
subgroups were evaluated by using a Mann-Whitney test.
For comparison of unmatched, continuous variables, the 2-
tailed unpaired Student t test was used. For linear regression
analysis, Spearman’s rank correlation coefficient r and the p
value derived from a two-tailed Student t-distribution were
computed. Spearman’s correlation coefficient r is a measure
for the size of the effect. To determine how strong the corre-
lation found is, the classification of Cohen can be used [36]:
r = .10 corresponds to a weak effect, r = .30 corresponds to a
medium effect, r = .50 corresponds to a strong effect.
Statistical significance was assigned for p < 0.05.
Computations were performed using MedCalc (MedCalc
Software, Mariakerke, Belgium).
Results
[18F]Galacto-RGD uptake after MI
In vivo PET/CT imaging demonstrated clear [18F]Galacto-
RGD uptake in 5 (42%) patients within the area of infarction
as determined by cardiac MRI and [13N]NH3 PET (Fig. 1).
Note that in some patients, areas of uptake also extended to
areas of myocardium adjacent to infarct zones (Fig. 2). The
corresponding lesion/remote, lesion/blood, and lesion/liver ra-
tios are reported in Fig. 3. Note also that in some patients,
there was even slightly lower uptake in the infarct zone com-
pared with normal myocardium resulting in negative lesion/
remote ratios. There was no correlation between lesion/remote
ratio and infarct-to-scan time (lesion/remote: r = − 0.31, p =
0.33, Fig. 3D). As [18F]Galacto-RGD shows a relatively high
physiological uptake in the liver, lesion/liver ratios were low.
Correlation of [18F]Galacto-RGD uptake with infarct
type and infarct size
The area of [18F]Galacto-RGD uptake correlated significantly
with the infarct size as determined by [13N]NH3 perfusion
PET. Moreover, the intensity of [18F]Galacto-RGD uptake
measured as lesion/remote ratio correlated significantly with
the infarct size as determined by [13N]NH3 PET. Note, how-
ever, that the correlation was only moderate, as in some pa-
tients an intense [18F]Galacto-RGD uptake could be seen de-
spite a relatively small infarct zone. No difference regarding
[18F]Galacto-RGD uptake was observed in STEMI vs.
NSTEMI cases (18.7 ± 34.6% vs. 19.4 ± 43.0%, p = .97).
Results are summarized in Fig. 4.
Correlation of [18F]Galacto-RGD uptake and blood
flow
Based on the AHA 17-segment model, tracer uptake of
[18F]Galacto-RGD and blood flow, as measured by
[13N]NH3, were correlated for each segment. A weak to mod-
erate, but significant, inverse correlation of blood flow and
[18F]Galacto-RGD uptake for all segments was measured
(Fig. 5A). Note that areas of high [18F]Galacto-RGD uptake
were also seen in areas with relatively normal or only slightly
impaired blood flow as well. This is in line with the visual
observation mentioned above, confirming that [18F]Galacto-
RGD uptake could be measured not only within infarcted
areas but also adjacent to infarcted areas in the border zone.
In a subgroup analysis, only areas of infarcted myocardium
using a threshold of blood flow less than 0.5 ml/min/g were
evaluated. In these areas, a substantially stronger and highly
significant inverse correlation of blood flow and [18F]Galacto-
RGD uptake (Fig. 5B) was found. This shows that
[18F]Galacto-RGD uptake is not substantially biased by un-
specific perfusion effects, as good uptake was notable also in
segments with very little perfusion.
Discussion
This is the first study investigating the association between
myocardial blood flow and αvβ3 integrin expression in pa-
tients after MI using [18F]Galacto-RGD and [13N]NH3 PET,
respectively. [18F]Galacto-RGD uptake in and adjacent to
areas of MI could be visualized and quantified in a subset of
patients and significantly correlated with infarct size and im-
pairment of myocardial blood flow. Thus, PET/CT imaging of
αvβ3 integrin expression could represent a novel promising
imaging approach for the evaluation of myocardial angiogen-
esis, which is potentially affecting left ventricular remodeling.
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Patterns and intensity of [18F]Galacto-RGD uptake
While [18F]Galacto-RGD has already extensively been evalu-
ated for imagingαvβ3 expression in malignant lesions, studies
with [18F]Galacto-RGD and PET also indicated sufficient sig-
nal intensity for visualizing increased αvβ3 integrin expres-
sion in benign lesions such as chronic skin inflammation and
infarcted myocardium [20, 37]. Up to now, data on imaging of
αvβ3 after myocardial infarction is limited [18, 23].
This study demonstrates that αvβ3 expression can be vi-
sualized and quantified by [18F]Galacto-RGD PET in or adja-
cent to areas of myocardial infarction in humans. Previous
preclinical data in a rat model of ischemia-reperfusion strong-













Fig. 2 Patterns of [18F]Galacto-RGD uptake in myocardial infarction.
[13N]NH3 and [
18F]Galacto-RGD PET as well as late enhancement
cardiac MRI is shown (A: short axis; B: vertical long axis; C: polar
maps). A large area of infarction with predominantly transmural
contrast enhancement is shown in cardiac MRI in the anterior and
anteroseptal wall with severely impaired blood flow in [13N]NH3 PET
(arrows). [18F]Galacto-RGD PET shows tracer uptake in the area of
infarction; however, note that the tracer uptake also extends to areas
adjacent to the infarcted areas into myocardium with normal or only
slightly impaired blood flow (arrows), which is especially well
demonstrated in the polar maps (C)
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Fig. 3 Quantitative analysis of [18F]Galacto-RGD uptake. Box-and-
whisker plots of [18F]Galacto-RGD uptake in infarct areas of all patients,
depicted as lesion/remote-ratio (A), lesion/blood-ratio (B), and lesion/
liver ratio (C). In 5 patients there was clear tracer uptake visible with a
lesion/blood ratio of 1 or more. In the other patients, there was only little
tracer uptake, which in 3 patients was even lower than in normal myo-
cardium. Note that lesion/liver ratios were relatively low due to physio-
logically pronounced liver uptake of [18F]Galacto-RGD. There was no
correlation between [18F]Galacto-RGD lesion/remote-ration and infarct-
to-scan time (D)
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for αvβ3 expression and correlated with myocardial angio-
genesis on a immunohistochemical level [20]. Moreover, it
has been shown that [18F]Galacto-RGD has a high affinity
and selectivity for the αvβ3 integrin in vitro as well as
receptor-type specific accumulation in vivo in αvβ3 integrin
positive tumors preclinically and clinically [19, 27]. In
summary, these data suggest that the PET signal measured
with [18F]Galacto-RGD in our study represents myocardial
αvβ3 expression. However, from the PET signal alone, it
cannot be differentiated whether the signal derives predomi-
nantly fromαvβ3 expressed on endothelial cells or from other
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Fig. 4 Correlation of
[18F]Galacto-RGD uptake and
infarct type/size. No difference in
[18F]Galacto-RGD uptake
depending on infarct type
(STEMI vs. NSTEMI) was
observed (A). Also, the
correlations of the extent of
[18F]Galacto-RGD uptake (B)
and of the intensity of
[18F]Galacto-RGD uptake (C)
with the infarct area as determined
by [13N]NH3 perfusion PET are
displayed. A significant correla-
tion of both area and intensity of
[18F]Galacto-RGD uptake with
infarct size was found. However,
the correlation was only moderate
with single patients showing in-
tense and/or extensive
[18F]Galacto-RGD uptake despite
































































Spearman’s R = -0.750 
p < 0.0001
Spearman’s R = -0.385 
p = 0.016
Fig. 5 Correlation of [18F]Galacto-RGD uptake and myocardial blood
flow. Results are shown for all myocardial segments (17-segment
model; A) and for the infarcted segments only (B, threshold below
0.5 ml/min/g). A significant but moderate inverse correlation of
[18F]Galacto-RGD uptake and blood flow for all segments was measured.
Note, however, that some segments showed intense [18F]Galacto-RGD
uptake but only slightly or no impaired blood flow. This corresponds to
the visual analysis where [18F]Galacto-RGD uptake was seen not only
within but also adjacent to areas of infarction in the border zone. When
only looking at segments with infarction (B), the inverse correlation was
more pronounced, which shows that uptake of [18F]Galacto-RGD was
not dominated by unspecific perfusion effects
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MI including macrophages or myocardial myofibroblasts.
One study using the integrin αvβ3/αvβ5 specific SPECT
tracer RIP has reported a predominant association of tracer
uptake and myocardial myofibroblasts [38]. However, in a
study using [18F]Galacto-RGD in a rat model of ischemia-
reperfusion, tracer uptake was predominantly associated with
endothelial cells and therefore myocardial angiogenesis [14].
In another study by Dobrucki et al., it has been demonstrated
that angiogenesis in a rat model of infarction may not only be
visualized by performing SPECT after the administration of a
[99mTc]-labeled chelate-peptide conjugate containing an RGD
motif; it has also been shown that the angiogenic response
may be altered by the application of insulin-like growth
factor-1 and then monitored using this imaging approach [31].
Furthermore, we observed an increased [18F]Galacto-RGD
uptake both in the center of the infarct and in the border zone.
It has already been shown that there is an increased
neoangiogenesis in the border zone of the infarct, which is
associated with an increased αvβ3 expression. This has been
demonstrated in a study on a rat infarct model, where an in-
creased CD31 expression in the infarct periphery was found
together with an increased uptake of a [68Ga]-labeled RGD
PET tracer as a sign of increased αvβ3 expression 4 weeks
after infarct induction [21]. Furthermore, it has recently been
shown that increased neoangiogenesis also occurs in the in-
farct center through the formation of new vessels sprouting
from the endocardium [39].
These preclinical data support that also in the clinical set-
ting, targeting of αvβ3 expression by [18F]Galacto-RGD
might be an interesting surrogate parameter of ventricular an-
giogenesis and subsequent remodeling and could also be used
for the evaluation or monitoring of new therapeutic
approaches.
Correlation of [18F]Galacto-RGD uptake, blood flow,
and infarct size
The relationship between αvβ3 expression and myocardial
perfusion after myocardial infarction has not yet been suffi-
ciently investigated. In this study, the tracer uptake of
[18F]Galacto-RGD correlated moderately with infarct size
and was more pronounced in areas with more restricted blood
flow as quantified by [13N]NH3 PET. Although the correla-
tions found are only moderate, it should be noted that it was
determined using Spearman’s rank correlation coefficient, a
test that is insensitive to outliers, and that a strong effect of this
correlation can be assumed, which means that the correlation
is highly likely to be relevant [36]. Therefore, these data sug-
gest that the severity of MI is interconnected to the intensity of
integrin αvβ3 expression about 3–4 weeks after MI.
Moreover, [18F]Galacto-RGD uptake could also be seen adja-
cent to the infarcted areas in myocardial segments with no or
only little impairment of blood flow. This suggests that
myocardial αvβ3 expression is not limited to the infarct zone
itself but can also be found adjacent to it in the border zone.
This supports the hypothesis that tracer uptake correlates with
myocardial angiogenesis, which should be most pronounced
in the border zone.
The finding that [18F]Galacto-RGD uptake was even stron-
ger inversely correlated to blood flow within the infarct zones
themselves indicates that tracer uptake is not dominated by
unspecific perfusion effects and strongly suggests specific
tracer uptake. There is first evidence that increased αvβ3 ex-
pression after MI is a favorable prognostic factor regarding
LV remodeling [18], which we could not show in this feasi-
bility study due to the small sample size.
We observed that the mean uptake of [18F]Galacto-RGD
was several times lower than reported for αvβ3 integrin ex-
pressing tumors [28, 40, 41]. This can on the one hand be
explained by biological phenomena, as preclinical data sug-
gest that [18F]Galacto-RGD predominantly binds to endothe-
lial cells after MI, which are of relatively low density, when
compared with a tumor with integrin expression both on en-
dothelial and tumor cells. On the other hand, physical factors
might play a role as the volume of MI zones was smaller
compared with most tumor lesions in the reported studies,
which usually were larger than 20 mm in diameter. As the
spatial resolution of PET is limited, spill-out to adjacent tissue
with low tracer uptake artificially reduces the measured uptake
in lesions smaller than ~ 20–25 mm, the so-called partial-vol-
ume effect. To improve uptake and target-to-background ra-
tios, a potential solution might be tracer optimization by
multimerization, which has been shown to increase signal
intensity from αvβ3 integrin expressing tissues [42, 43].
However, a comparison of various monomeric and multimeric
integrin αvβ3 imaging tracers from our group showed no
significant differences concerning image contrast in a preclin-
ical model of myocardial infarction [22].
Comparison to existing studies in humans
To date, there are only a limited number of studies on PET
imaging of the αvβ3 integrin after myocardial infarction. In
one study 27 patients (21 patients after STEMI and 7 patients
with chronic coronary artery occlusion (CTO)) and 9 healthy
subjects were examined using [18F]-fluciclatide (another
αvβ3 targeting tracer) PET/CT and MRI [18]. In line with
our study, it was demonstrated that there is an increased
αvβ3 integrin expression in the infarct area. Interestingly, an
increased αvβ3 expression was associated with an improve-
ment of wall motion. It was also shown that in patients with
CTO no uptake was visible in old infarction scars and in
healthy volunteers no myocardial uptake was detectable. A
major difference to our study is that no information on perfu-
sion was provided. Accordingly, the findings that integrin
expression correlated inversely with blood flow and that
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integrin expression was elevated in the perfused border zone
are particularly new. In another study, 23 patients after myo-
cardial infarction were examined with [68Ga]-PRGD2, anoth-
er αvβ3 integrin tracer, using PET/CT [23]. Similar to our
study, an increased αvβ3 expression was found in the infarct
area and integrin expression was elevated in the patient pop-
ulation up to 2.5 months after infarction.
Comparison to other imaging modalities
Concerning alternative modalities for molecular imaging
of αvβ3 expression, SPECT imaging has already been
used clinically in patients after MI, however has a lower
sensitivity and limited resolution [32]. Concerning MRI,
several preclinical studies reported the successful imag-
ing of αvβ3 integrin expression in atherosclerosis [44,
45]. The higher resolution of MRI combined with ex-
cellent soft tissue contrast surely is an advantage com-
pared with PET. However, in MRI significantly higher
amounts of contrast agents and probes have to be used
compared with PET, which requires only the adminis-
tration of probes in the microgram range. Therefore,
side effects of most PET tracers are limited or not pres-
ent at all. This facilitates translation of results of PET
tracers into the clinical setting, as demonstrated for
[18F]Galacto-RGD.
Study limitations
The main limitation of our study is the small patient popula-
tion. However, this study was primarily focused on the
aim to investigate the association of myocardial blood
flow with αvβ3 expression in patients after MI and we
were the first to describe the inverse relationship.
Another general limitation is that the radiotracer
[18F]Galacto-RGD exhibits a relatively high liver up-
take. This may complicate the assessment of integrin
expression in case of inferior wall infarctions.
However, it has to be stressed that this uptake has to
be classified as specific, because the comparison of dif-
ferent αvβ3-targeting tracers with different chemical
structure, size, and also polarity showed that they all
had an intensive liver uptake, which could be blocked
effectively [42]. Finally, the variable timepoint of scan-
ning after MI represents a limitation, which was mainly
due to logistic reasons, as depending on the general
state of the patients, the quite extensive imaging proto-
col could not be performed in all patients to the exactly
same time after MI. On the other hand, in our patient
cohort, which is concordant with the other αvβ3
integrin PET imaging studies in patients after myocardi-
al infarction [18, 23], there was no correlation between
the time period of image acquisition after MI and
[18F]Galacto-RGD uptake, so that timing seems to have
only a minor impact at least in the first couple of weeks
after infarction.
Conclusion
We demonstrate that [18F]Galacto-RGD PET/CT allows the
visualization and quantification of integrin αvβ3 expression
in a subset of patients after MI and that αvβ3 expression is
inversely correlated with myocardial blood flow in this sce-
nario. Based on these promising results, further prospective
studies are justified and warranted to test the clinical value of
PET-based αvβ3 expression assessment as a prognostic
marker for left ventricular remodeling and prognosis after
MI. Combining the high sensitivity of PET with the excellent
anatomical detail provided by CT or MRI in hybrid systems,
this approach has the potential to map specific molecular sig-
nals of the myocardium with high accuracy [46].
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